AAFA says the investigation opens an opportunity to address what patients report as the primary reason why people don’t adhere to their asthma treatment: the cost of prescribed asthma medication.
AAFA says the investigation opens an opportunity to address what patients report as the primary reason why people don’t adhere to their asthma treatment: the cost of prescribed asthma medication.
Read More
GlaxoSmithKline announced positive preliminary results from its phase III trial of its Arexvy RSV Vaccine in adults aged 50 to 59.
Read MoreA study of patients treated for COPD found the inhaler, Wixela Inhub, is a substitutable version of the dry powder inhaler Advair Diskus.
Read More
In clinical trials, the vaccine significantly reduced the risk of developing RSV-associated lower respiratory tract disease by 82.6% and reduced the risk of developing severe RSV-associated lower respiratory tract disease by 94.1% in adults age 60 and older.
Read More
FDA panel favors approval for two RSV vaccines, ‘Tripledemic’ hits US households, and a monoclonal antibody may be ready for next season—here are five RSV stories you should check out this week.
Read More
A monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma.
Read More
A phase III trial investigating the GSK RSV vaccine candidate for adults aged 60 years and above exceeded its primary endpoint with no unexpected safety concerns observed, the company announced.
Read More
The FDA revoked the emergency use authorization for the monoclonal antibody Sotrovimab in the Northeastern US due to its ineffectiveness against the Omicron BA.2 subvariant.
Read MoreHealth Canada has approved GlaxoSmithKline and Medicago’s Covifenz COVID-19 vaccine, a plant-based virus-like particles, recombinant, adjuvanted vaccine, for adults age 18-64.
Read More
Sanofi and GSK will submit data from both their booster and Phase 3 efficacy trials to the FDA and other international regulatory agencies for authorization of their Sanofi-GSK COVID-19 vaccine.
Read More
Philip Morris is competing with a US private equity firm to buy the asthma medicine company Vectura.
Read More
The approval makes Nucala the first and only targeted biologic treatment to be approved for patients with Hypereosinophilic Syndrome in the US.
Read More
The US FDA has approved a new indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the treatment of asthma in patients aged 18 years and older.
Read More
GSK recalled several cough syrup products after the company discovered a flaw on the dosing measuring cups.
Read More
GSK told Reuters that its previous flu pandemic vaccine, which used some of the same ingredients as COVID-19 vaccines currently under development, was not linked to a rise in cases of narcolepsy, suggesting the link is to the H1N1 flu virus itself, not the vaccine.
Read MoreGlaxoSmithKline has issued two grants totaling $380,000 to the American Thoracic Society’s COVID-19 Crisis Fund.
Read More
The US FDA has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe eosinophilic asthma.
Read MoreThe US FDA has approved two new methods for administering Nucala (mepolizumab), including an autoinjector and a pre-filled safety syringe that can be self-administered by patients or caregivers.
Read MoreUS regulatory advisors are questioning the effectiveness of GlaxoSmithKline’s biologic Nucala as a treatment for patients experiencing a sudden worsening of COPD. Nucala (mepolizumab) is a monoclonal antibody – already...
Read MoreThe FDA has approved the use of Arnuity Ellipta, a once-daily inhaled corticosteroid for the maintenance treatment of asthma in children from as young as 5 years.
Read MoreIn total, GSK will present data from 61 abstracts, including five oral presentations and 42 poster presentations.
Read MoreTrelegy Ellipta, a triple therapy delivered in a single inhaler, reduces moderate to severe exacerbations in COPD to a greater extent than dual-inhaler therapy in patients at high risk for exacerbations, according to the IMPACT...
Read MoreTrelegy Ellipta, a triple-combination LABA/ICS inhaled treatment for COPD, has been approved for an expanded indication by the FDA, according to GlaxoSmithKline and Innoviva Inc.
Read More
Severe asthma patients who are uncontrolled despite receiving Xolair (omalizumab) experienced improved asthma control when switched to Nucala (mepolizumab), according to GlaxoSmithKline.
Read More
